Comparison of different serological assays for SARS-CoV-2 in real life.

ABSTRACT:

Background

The emergence of the global SARS-CoV-2 pandemic required the rapid and large-scale deployment of PCR and serological tests in different formats.

Objectives

Real-life evaluation of these tests is needed. Using 168 samples from patients hospitalized for COVID-19, non-hospitalized patients but infected with SARS-CoV-2, patients participating in screening campaigns, and samples from patients with a history of other seasonal coronavirus infections, we evaluated the clinical performance of 5 serological assays widely used worldwide (WANTAI®, BIORAD®, EUROIMMUN®, ABBOTT® and LIAISON®).

Results

For hospitalized patients, all these assays showed a sensitivity of 100 % from day 9 after the symptoms onset. On the other hand, sensitivity was much lower for patients who

SUBMITTER: Brochot E 

PROVIDER: S-EPMC7396207 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature